Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859003 | 0.85 | NOD1 (0.42) | GLO1NOD1FOLH1PTGS1GSTK1 | |
| SCHEMBL858566 | 0.82 | ALDH1A1 (0.51) | — | |
| SCHEMBL858574 | 0.77 | PTGS1 (0.54) | GLO1NOD1FOLH1PTGS1GSTK1 | |
| SCHEMBL15318518 | 0.75 | PTGS1 (0.52) | GLO1NOD1FOLH1PTGS1GSTK1 | |
| SCHEMBL8031472 | 0.74 | APEX1 (0.44) | — | |
| SCHEMBL13295134 | 0.74 | ALDH1A1 (0.45) | GLO1PTGS1GSTK1 | |
| SCHEMBL859001 | 0.73 | PTGS1 (0.49) | GLO1NOD1PTGS1GSTK1 | |
| SCHEMBL858563 | 0.73 | PTGS1 (0.48) | GLO1PTGS1GSTK1 | |
| SCHEMBL20856994 | 0.73 | PTGS1 (0.48) | GLO1PTGS1GSTK1 | |
| SCHEMBL859188 | 0.71 | SMN1; SMN2 (0.44) | GLO1PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-7994222-B2 | Poly(ADP-ribose) polymerase inhibitor is preferably 3-nitro-4-iodobenzamide; administered orally, topically, parenerally, transdermally, or rectally; anticarcinogenic and antidiabetic agents; obesity, cardiovascular disease | BIPAR SCIENCES, INC. (US) | 2011-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | GLO1 2118/4885NOD1 3579/4885FOLH1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.